China SXT Resets Financing Floor Price to $0.20 After 1-for-80 Reverse Split
SXTC is trading near its 52-week low of $3 (3.0% above the low) on light trading volume (0.1× avg).
Summary
China SXT Pharmaceuticals amended its pre-paid purchase agreement to reduce the Floor Price from $16.00 to $0.20 per share, restoring the investor's ability to convert at deeply discounted prices after the 1-for-80 reverse split.
Key Events · Financing and Capital Events · SXTC
-
Floor Price Reset to $0.20
Amendment No.1 to the Securities Purchase Agreement reduces the Floor Price from $16.00 (post-reverse-split adjusted) to $0.20 per share, effective August 27, 2026.
-
Reverse Split Triggered Adjustment
The 1-for-80 reverse split on August 10, 2026 automatically raised the Floor Price from $0.20 to $16.00, making the financing impractical at current market prices.
-
Dilution Risk Restored
At a $0.20 Floor Price, the investor can convert pre-paid purchases into Class A ordinary shares at a fraction of the current $3.09 market price, significantly increasing potential dilution.
-
Registration Statement Amended
The Company filed Amendment No.1 to its Form F-3 registration statement in connection with the Floor Price reduction.
Analysis · SXTC · Life Sciences
China SXT Pharmaceuticals amended its $31.5 million pre-paid purchase agreement to cut the Floor Price from $16.00 to $0.20 per share. The 1-for-80 reverse split on August 10 had automatically raised the Floor Price to $16.00, which would have made the financing nearly unusable given the stock now trades around $3.09. Resetting the Floor Price to $0.20 restores the investor's ability to convert at deeply discounted prices, effectively re-enabling a highly dilutive financing mechanism. This is a material change to the terms of the existing agreement, not a routine update.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTC was trading at $3.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $3.00 to $83,758.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.